New Drug Approvals

Home » Phase2 drugs » Celgene oral Crohn’s drug GED-0301, Mongersen impresses in Phase II

Celgene oral Crohn’s drug GED-0301, Mongersen impresses in Phase II

DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

ORGANIC SPECTROSCOPY

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

Categories

Blog Stats

  • 2,652,034 hits

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,428 other followers

add to any

Share

Celgene签署$26亿协议获克罗恩病反义药物GED-0301

Nogra制药,Celgene

Nogra Pharma Limited

公司寡核苷酸(Oligonucleotides)

克罗恩病(Crohn’s disease)

Shares in Celgene Corp have risen steadily following promising mid-stage data of its closely-watched Crohn’s disease drug mongersen.

Company Nogra Pharma Ltd.
Description Antisense oligonucleotide targeting SMAD family member 7 (MADH7; SMAD7)
Molecular Target SMAD family member 7 (MADH7) (SMAD7)
Mechanism of Action
Therapeutic Modality Nucleic acid: Linear RNA: Antisense
Latest Stage of Development Phase II
Standard Indication Crohn’s disease
Indication Details Treat moderate to severe Crohn’s disease
Regulatory Designation
Partner

Celgene Corp.

Mongersen (GED-0301) from Celgene Corp. (NASDAQ:CELG) produced clinical remission rates as high as 65.1% in a Phase II trial in 166 patients with moderate to severe Crohn’s disease, according to an abstract published in advance of the United European Gastroenterology’s meeting in Vienna.

In the trial, 55% of patients receiving 40 mg/day of mongersen and 65.1% of those receiving 160 mg/day achieved clinical remission compared with 9.5% of placebo patients (p<0.0001 for both). A cohort receiving 10 mg/day achieved a clinical remission rate of 12.2%, which was not significantly better than placebo.

The study’s primary outcomes were clinical remission, defined by a CDAI score less than 150 at day 15 and maintained for more than two weeks, and safety. Mongersen was well-tolerated, and toxicities associated with systemically active antisense therapies were not observed.

The study’s secondary endpoint is clinical response, defined as a CDAI score reduction of 100 points at day 28. Those rates were dose-dependent: 36.6%, 57.5% and 72.1% for the low, medium and high doses compared with 16.7% for placebo.

Celgene said it plans to start Phase III testing of mongersen shortly. The company paid $710 million up front to obtain exclusive, worldwide rights to the antisense oligonucleotide targeting SMAD family member 7 (MADH7; SMAD7) from Nogra Pharma Ltd. (Dublin, Ireland) in April. Nogra is eligible for $1.9 billion in milestones, plus tiered single-digit royalties.

 GED-0301, an antisense oligonucleotide targeting the SMAD7 gene, is in phase II clinical trials at Nogra Pharma for the oral treatment of moderate to severe Crohn’s disease.

生物技术公司新基(Celgene)从爱尔兰制药商Nogra制药手中获得了一种处于后期临床开发的克罗恩病(Crohn’s disease)药物GED-0301。GED-0301是一种口服反义药物,靶向于Smad7信使RNA(mRNA),该药开发用于中度至重度克罗恩病 的治疗。反义药物是一种合成的核酸拷贝,旨在结合导致疾病的基因的mRNA,关闭基因的表达;口服;【Celgene签署$26亿协议获克罗恩病反义药物 GED-0301】http://www.hfoom.com/product/20140425/8311.html

 

Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract suffered by approximately one million patients in the United States. The two most common forms of IBD are Crohn’s disease (CD) and ulcerative colitis (UC). Although CD can affect the entire gastrointestinal tract, it primarily affects the ilieum (the distal or lower portion of the small intestine) and the large intestine. UC primarily affects the colon and the rectum. Current treatment for both CD and UC include aminosalicylates (e.g., 5- aminosalicylic acid, sulfasalazine and mesalamine), antibiotics (e.g., ciprofloxacin and metronidazole), corticosteroids (e.g., budesonide or prednisone), immunosuppressants (e.g., azathioprine or methotrexate) and tumor necrosis factor (TNF) antagonists (e.g., infliximab (Remicade®)). Patient response to these therapies varies with disease severity and it can vary over cycles of active inflammation and remission. Moreover, many of the current therapies for IBD are associated with undesirable side effects.

Although the etiologies of CD and UC are unknown, both are considered inflammatory diseases of the intestinal mucosa. Recent studies have demonstrated that TGF-β 1 acts as a potent immunoregulator able to control mucosal intestinal inflammation. TGF-βΙ binds a heterodimeric transmembrane serine/threonine kinase receptor containing two subunits, TGF-βΙ Rl and TGF-βΙ R2. Upon ligand binding, the TGF-βΙ Rl receptor is phosphorylated by the constitutively active TGF-βΙ R2 receptor and signal is propagated to the nucleus by proteins belonging to the SMAD family. Activated TGF-β Ι Rl directly phosphorylates SMAD2 and SMAD3 proteins, which then interact with SMAD4. The complex of SMAD2/SMAD3/SMAD4 translocates to the nucleus and modulates the transcription of certain genes.

Additional studies have demonstrated that another SMAD protein, SMAD7, also plays a role in inflammation. SMAD7, an intracellular protein, has been shown to interfere with binding of SMAD2/SMAD3 to the TGF-βΙ Rl preventing phosphorylation and activation of these proteins. Further, increased expression of SMAD7 protein is associated with an inhibition of TGF-βΙ mediated-signaling. Mucosal samples from IBD patients are characterized by high levels of SMAD7 and reduced levels of phosphorylated-SMAD3 indicating that TGF-βΙ -mediated signaling is compromised in these patients.

Recent studies have focused on SMAD7 as a target for treating patients suffering from IBD.

Such therapies include anti-SMAD7 antisense therapies. As such, there is a need for methods based on predictive biomarkers that can be used to identify patients that are likely (or unlikely) to respond to treatment with anti- SMAD7 therapies.

GTCGCCCCTTCTCCCCGCAGC

GED-0301, Mongersen

Phosphorothioate antisense oligonucleotide targeting human mothers against decapentaplegic homolog 7 (SMAD7) gene, whose sequence is 5′-GTCGCCCCTTCTCCCCGCAGC-3′, wherein ‘C’ at postions 3 and 16 is 5-methyl 2′-deoxycytidine 5′-monophosphate

WO 2004087920

http://www.google.com/patents/WO2004087920A1?cl=en

…………………………

WO 2013037970

http://www.google.com/patents/WO2013037970A1?cl=en

…………………

WO 2013158868

http://www.google.com/patents/WO2013158868A1?cl=en

……………………………………………

WO 2014140333

http://www.google.com/patents/WO2014140333A1?cl=en

5*-GTCGCCCCTTCTCCCCGCAGC-3* (SEQ ID NO: 3).

 

Reference
1 BADARU, A.; PIHOKER, C.: ‘Type 2 diabetes in childhood: clinical characteristics and role of beta-cell autoimmunity‘ CURR. DIAB. REP. vol. 12, 2012, pages 75 – 81
2 * BHAT ET AL: “Antisense inhibition of 11betahydroxysteroid dehydrogenase type 1 improves diabetes in a novel cortisone-induced diabetic KK mouse model“, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 365, no. 4, 20 November 2007 (2007-11-20), pages 740-745, XP022384861, ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2007.11.032
3 * GUTIERREZ-AGUILAR ET AL: “Minor contribution of SMAD7 and KLF10 variants to genetic susceptibility of type 2 diabetes“, DIABETES & METABOLISM, PARIS, AMSTERDAM, NL, vol. 33, no. 5, 10 October 2007 (2007-10-10), pages 372-378, XP022327080, ISSN: 1262-3636, DOI: 10.1016/J.DIABET.2007.06.002
4 * H. Y. CHEN ET AL: “The Protective Role of Smad7 in Diabetic Kidney Disease: Mechanism and Therapeutic Potential“, DIABETES, vol. 60, no. 2, 27 October 2010 (2010-10-27), pages 590-601, XP55071874, ISSN: 0012-1797, DOI: 10.2337/db10-0403
5 HONG, S. ET AL.: ‘Smad7 sensitizes tumor necrosis factor induced apoptosis through the inhibition of antiapoptotic gene expression by suppressing activation of the nuclear factor-kappaB pathway‘ CANCER RES. vol. 67, 2007, pages 9577 – 9583
6 HOOK, S. M. ET AL.: ‘Smad2: A candidate gene for the murine autoimmune diabetes locus Idd21.1‘ 1. CLIN. ENDOCRINOL. METAB. vol. 96, 2011, pages E2072 – E2077
7 KAWAMOTO, K. ET AL.: ‘Transforming growth factor beta 1 (TGF-?1) and rapamycin synergize to effectively suppress human T cell responses via upregulation of FoxP3+ Tregs‘ TRANSPL. IMMUNOL. vol. 23, 2010, pages 28 – 33
8 LI, M. O.; FLAVELL, R. A.: ‘TGF-beta: a master of all T cell trades‘ CELL vol. 134, 2008, pages 392 – 404
9 * LIANG Y ET AL: “Reduction in Glucagon Receptor Expression by an Antisense Oligonucleotide Ameliorates Diabetic Syndrome in db/db Mice“, DIABETES, AMERICAN DIABETES ASSOCIATION, US, vol. 53, February 2004 (2004-02), pages 410-417, XP002995165, ISSN: 0012-1797, DOI: 10.2337/DIABETES.53.2.410
10 * LU ZHU ET AL: “Unraveling the biological functions of Smad7 with mouse models“, CELL & BIOSCIENCE, BIOMED CENTRAL LTD, LONDON, UK, vol. 1, no. 1, 28 December 2011 (2011-12-28), page 44, XP021132085, ISSN: 2045-3701, DOI: 10.1186/2045-3701-1-44
11 LUO, X. ET AL.: ‘Systemic transforming growth factor-?1 gene therapy induces Foxp3+ regulatory cells, restores self-tolerance, and facilitates regeneration of beta cell function in overtly diabetic nonobese diabetic mice‘ TRANSPLANTATION vol. 79, 2005, pages 1091 – 1096
12 MARGOLLES-CLARK, E. ET AL.: ‘Small molecule costimulatory blockade: organic dye inhibitors of the CD40-CD154 interaction‘ J. MOL. MED. vol. 87, 2009, pages 1133 – 1143
13 * MIZOBUCHI TERUAKI ET AL: “Differential expression of Smad7 transcripts identifies the CD4+CD45RChigh regulatory T cells that mediate type V collagen-induced tolerance to lung allografts“, THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 171, no. 3, 1 August 2003 (2003-08-01), pages 1140-1147, XP002430371, ISSN: 0022-1767
14 MONTELEONE, G. ET AL.: ‘A failure of transforming growth factor-?1 negative regulation maintains sustained NF-KB activation in gut inflammation‘ J. BIOL. CHEM. vol. 279, 2004, pages 3925 – 3932
15 MORITANI, M. ET AL.: ‘Abrogation of autoimmune diabetes in nonobese diabetic mice and protection against effector lymphocytes by transgenic paracrine TGF-?1‘ J. CLIN. INVEST. vol. 102, 1998, pages 499 – 506
16 * NORA G. SMART ET AL: “Conditional Expression of Smad7 in Pancreatic [beta] Cells Disrupts TGF-[beta] Signaling and Induces Reversible Diabetes Mellitus“, CELL, vol. 88, no. 2, 31 January 2006 (2006-01-31), page 561, XP55071875, ISSN: 0092-8674, DOI: 10.1371/journal.pbio.0040039
17 OLIVIERI, A. ET AL.: ‘Serum transforming growth factor ?1 during diabetes development in non-obese diabetic mice and humans‘ CLIN. EXP. IMMUNOL. vol. 162, 2010, pages 407 – 414
18 Remington’s Pharmaceutical Sciences‘, 1990, MACK PUBLISHING COMPANY
19 ROEP, B. O. ET AL.: ‘Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes‘ NAT. REV. IMMUNOL. vol. 4, 2004, pages 989 – 997
20 * S. M. HOOK ET AL: “Smad2: A Candidate Gene for the Murine Autoimmune Diabetes Locus Idd21.1“, JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 96, no. 12, 5 October 2011 (2011-10-05), pages E2072-E2077, XP55071877, ISSN: 0021-972X, DOI: 10.1210/jc.2011-0463
21 SHODA, L. K. ET AL.: ‘A comprehensive review of interventions in the NOD mouse and implications for translation‘ IMMUNITY vol. 23, 2005, pages 115 – 126
22 SMART, N. G. ET AL.: ‘Conditional expression of Smad7 in pancreatic beta cells disrupts TGF-beta signaling and induces reversible diabetes mellitus‘ PLOS BIOL. vol. 4, 2006, page E39
23 WALLBERG, M. ET AL.: ‘An islet-specific pulse of TGF-? abrogates CTL function and promotes ? cell survival independent of Foxp3+ T cells‘ J. IMMUNOL. vol. 186, 2011, pages 2543 – 2551
24 YAN, X.; CHEN, Y. G.: ‘Smad7: not only a regulator, but also a cross-talk mediator of TGF-beta signalling‘ BIOCHEM. J. vol. 434, 2011, pages 1 – 10
WO2003037368A2 * Oct 31, 2002 May 8, 2003 Andreas Steinbrecher Smad7 inhibitors for the treatment of cns diseases
WO2009129544A1 * Apr 20, 2009 Oct 22, 2009 Baxter International Inc. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
WO2010054826A1 Nov 13, 2009 May 20, 2010 Giuliani International Limited Antisense compositions and methods of making and using same

1 Comment

  1. sarahbrooke7 says:

    Where are the clinical trials being held?

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

DR ANTHONY CRASTO

Follow New Drug Approvals on WordPress.com

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,428 other followers

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with GLENMARK PHARMACEUTICALS LTD, Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 30 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, Dr T.V. Radhakrishnan and Dr B. K. Kulkarni, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 30 year tenure till date Dec 2017, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 9 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 50 Lakh plus views on dozen plus blogs, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 19 lakh plus views on New Drug Approvals Blog in 216 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc

Personal Links

View Full Profile →

TWITTER

bloglovin

Follow my blog with Bloglovin The title of your home page You could put your verification ID in a comment Or, in its own meta tag Or, as one of your keywords Your content is here. The verification ID will NOT be detected if you put it here.
%d bloggers like this: